

Applicant : Roberto BURIONI
U.S. Serial No. : Not Yet Known
Filed : Herewith
Page : 2

IN THE CLAIMS:

Please cancel claims 6-10 without prejudice to the Applicant's rights to pursue the subject matters in a future application. Please add new claims 12-29:

1. (original) An human antibody, or its functional fragments, against the HCV E2 protein characterized in having an *in vivo* neutralizing activity.

2. (original) Antibody according to claim 1, being the antibody e137 characterized by having the following sequences of variable parts of the heavy chain and the light chain:

e 137 Heavy chain (HC)

LLEQSGSEVKVPGSSLKVSCKTSGGTFTSTYTFSWVRQAPGQGLEWMGGITPIIGIA
NYARNFQDRVTITADESTSTVYMEVRRLRSED TAVYYCAKTSEVTATRGRTFFYSA
MDVWGQGT

e 137 Light chain (LC)

MAELTQSPSFLSASVGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAASLTQS
GVPSRFSGSGSWTEFTLTISRLLQPEDFATYYCQHLNTYPWTFGQGT

3. (original) Antibody according to claim 1 being the antibody e301 characterized by having the following sequences of variable parts of the heavy chain and the light chain:

e 301 Heavy chain (HC)

LLEQSGSEVKKPGSSVRVSCCTTSGGTLSDYGFNWLRLQAPGQGPPEWMGGIIPFRRT
TYGQKFQGRLLTITADESTGATYMESSLRSDDTAVYYCAREKVS VLTGGKSLHYFE
YWGKGT

e 301 Light chain (LC)

MAELTQSPATLSVSPGERATLSCRASQSVSSRLAWYQQKRGQAPSLLIYDTSSRAT
GVPARFSASGSGTQFTLTISLQSEDFALYYCQQYNDWPSTFGQGT

4. (canceled)

Applicant : Roberto BURIONI
U.S. Serial No. : Not Yet Known
Filed : Herewith
Page : 3

5. (canceled)
6. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (new) A method for validating anti-HCV vaccines using the antibody according to claim 1.
13. (new) A method for validating anti-HCV vaccines using the antibody according to claim 2.
14. (new) A method for validating anti-HCV vaccines using the antibody according to claim 3.
15. (new) A nucleic acid coding for the antibody according to claim 1.
16. (new) A nucleic acid coding for the antibody according to claim 2.
17. (new) A nucleic acid coding for the antibody according to claim 3.
18. (new) A recombinant expression vector expressing the antibody of claim 1 in prokaryote or in eukaryote cells.

Applicant : Roberto BURIONI
U.S. Serial No. : Not Yet Known
Filed : Herewith
Page : 4

19. (new) A recombinant expression vector expressing the antibody of claim 2 in prokaryote or in eukaryote cells.
20. (new) A recombinant expression vector expressing the antibody of claim 3 in prokaryote or in eukaryote cells.
21. (new) A recombinant vector further comprising a nucleotide sequence coding for a signal peptide, substantially contiguous with the sequence coding for the antibody of claim 1, able to export this antibody out of the cell environment.
22. (new) A recombinant vector further comprising a nucleotide sequence coding for a signal peptide, substantially contiguous with the sequence coding for the antibody of claim 2, able to export this antibody out of the cell environment.
23. (new) A recombinant vector further comprising a nucleotide sequence coding for a signal peptide, substantially contiguous with the sequence coding for the antibody of claim 3, able to export this antibody out of the cell environment.
24. (new) A method of using the recombinant vector according to claim 21 in gene therapy.
25. (new) A method of using the recombinant vector according to claim 22 in gene therapy.
26. (new) A method of using the recombinant vector according to claim 23 in gene therapy.

Applicant : Roberto BURIONI
U.S. Serial No. : Not Yet Known
Filed : Herewith
Page : 5

27. (new) A composition for anti-HCV therapy comprising in a therapeutically effective amount at least one of the antibodies according to the claims.
28. (new) A composition according to claim 27 for topical use in gel, creme, ointment and ovule formulations.
29. (new) A method for the determination of the presence of antibodies directed against different epitopes of the HCV E2 protein in a biological fluid comprising the steps of:
 - a) determining the presence of antibodies in said fluid able to inhibit the binding of specific human Fab directed against different epitopes of protein E2;and
 - b) correlating the presence of so titered antibodies with clinical characteristics of patients, such as prognosis, responsiveness to therapy, infectivity.